The mixed vibe from Merck's earnings call underscores short-term pressures. A mixed bag of updated guidance, strong vaccine performance, and the VIOXX settlement are balanced by concerns over the Zetia/Vytorin controversy. The delay in releasing full ENHANCE results and its potential impact on Merck's cholesterol franchise creates uncertainty. The stock will face pressure in the next weeks. [-1]